XVARY Composite Score
46
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Lexicon develops drugs for heart failure, diabetes, and nerve pain.
How it gets paid
Last year Lexicon Pharm made $6M in revenue. Sotagliflozin was the main engine at $3.5M, or 58% of sales.
What just happened
Lexicon posted $1M in quarterly revenue and a $0.10 loss per share in the latest quarter.
At a Glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
-$0.63 fy2024 eps est
$31M fy2024 rev est
N/a operating margin
XVARY composite: 46/100 — below average
What They Do
Lexicon develops drugs for heart failure, diabetes, and nerve pain.
Genome5000™ studied nearly 5,000 genes and found more than 100 protein targets. That gives you a broad pipeline, not one bet. The punchline is the business still made only $6M in annual revenue, so the science is ahead of the sales.
How They Make Money
$6M
annual revenue
Sotagliflozin
$3.5M
+15.0%
LX9211
$1.0M
0.0%
Genome5000™ platform
$0.9M
54.0%
Other pipeline and licensing
$0.6M
0.0%
The Products That Matter
Approved heart failure drug
INPEFA (sotagliflozin)
$5.5M · 91.7% of revenue
This is the commercial story right now. INPEFA produced $5.5M of the company's $6M annual revenue, so if this ramp works the equity case gets oxygen. If it stalls, the story turns into a financing conversation fast.
current engine
Non-core revenue base
Other revenue
$0.5M · 8.3% of revenue
Only $0.5M came from everything outside INPEFA. That's the useful part of this line item: it tells you there is almost no second pillar under the income statement yet.
small support
Pipeline asset
Neuropathic pain candidate
pipeline · no product revenue shown here
The pipeline matters because the current business only generated $6M in annual revenue against a $716M market cap. In plain English: investors are already paying for what could come next, not just what ships today.
future bet
Key Numbers
$6M
TTM revenue
That is the whole top line. Compare it with a $716M market cap, and you see why investors are paying for hope, not sales.
n/a
op margin
Prior margin KPI failed sanity check — verify in filings. That margin means the business spent $8.15 for every $1 of sales. In plain English, losses swallowed the revenue.
$63M
debt
Debt is 8% of capital. That is not huge, but it matters when revenue is $6M.
1.55
beta
The stock moves 55% more than the market. Your nerves get extra exercise.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $63M (8% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Lexicon posted $1M in quarterly revenue and a $0.10 loss per share in the latest quarter.
Revenue rose 15% from a year ago. Gross margin was 96.3%, but operating costs still crushed the bottom line.
$1.0M
revenue
-$0.10
eps
96.3%
gross margin
the number that mattered
The $1M quarter matters because it shows the business is still tiny next to a $716M market cap.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is INPEFA failing to scale beyond an early launch bounce. With 91.7% of current revenue tied to one product, this is concentration risk first and everything else second.
Med
INPEFA uptake stalls
The commercial read improved after a $5.5M quarter versus a $3.14M estimate. It breaks if that momentum does not keep building from here.
Impact: 91.7% of the current $6M revenue base depends on this one drug.
Med
Losses stay louder than revenue
Estimated EPS is still -$0.63 and there is no usable P/E because there are no profits. If revenue ramps slower than expected, financing risk moves from background issue to main storyline.
Impact: you stay in a dilution-and-cash-runway conversation instead of graduating to an earnings conversation.
Med
The pipeline does not widen the story
Lexicon has a neuropathic pain candidate, but this snapshot shows no product revenue from it. If pipeline progress slips, investors are left with a one-drug commercial bet and very little backup.
Impact: the market keeps valuing LXRX on a narrow base business and a wide range of possible outcomes.
With 91.7% of the current $6M revenue base tied to INPEFA, a stumble there pressures both the income statement and the valuation story at the same time.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Calendar
Next earnings update
Use the next print to test whether the $5.5M quarterly revenue figure was the start of a trend or a one-quarter pop. Last full review: updated feb 27, 2026.
Trend
INPEFA sales ramp
This is the whole near-term stock story. One drug already drives 91.7% of revenue, so the ramp needs to keep looking real.
Risk
Cash still matters more than the pitch deck
With EPS estimated at -$0.63 and no earnings multiple, commercial traction has to outrun the market's financing anxiety.
Metric
Earnings predictability
20/100 tells you the financial picture is still moving around. If that number improves, the stock gets easier to underwrite. If it falls, volatility stays in charge.
Analyst Rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: nobody has a clean consensus to hide behind.
risk profile
volatile
small-cap healthcare rarely moves in straight lines. with a 1.55 beta and 5 / 100 price stability, LXRX is proving the point.
chart momentum
stock-specific
this name trades more on launch traction and pipeline headlines than on a smooth technical trend.
earnings predictability
20/100
the business is still changing shape, so the numbers can surprise you in both directions.
Source: institutional data
Institutional Activity
institutional ownership data for LXRX is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$1
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive